The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
The anti-malaria drug touted by U.S. President Donald Trump as a Covid-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.
The World Health Organization is discontinuing the WHO’s trials of the malaria drug hydroxychloroquine and the combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.
A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.
New information released by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19.
The U.S. Food and Drug Administration issued a warning to healthcare providers against administering the malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences’ experimental COVID-19 drug, remdesivir.
The U.S. Food and Drug Administration revoked the emergency use authorization for the malaria drug hydroxychloroquine as a treatment for COVID-19.
An article raising concern about the safety of using hydroxychloroquine as a treatment of COVID-19 that forced the World Health Organization to temporarily suspend a clinical study involving the drug was retracted.